| INTRODUCTION
Hepatitis B virus (HBV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) which leads to high mortality. 1 A complete eradication of HBV is rarely achieved because of the persistence covalently closed circular DNA (cccDNA) in host hepatocytes. 2 At present, interferon (IFN) is used as one of the firstline treatments for chronic hepatitis B (CHB). Researchers evidenced that therapy with IFN might control the viral replication. In detail, the function of IFN was to stimulate the cytotoxic T cell, lysing the infected hepatocytes and producing cytokines. 3 Compared with nucleos(t)ide analogues (NAs), resistance rarely occurred during PEG-IFN treatment. However, IFN therapy may cause several side-effects such as influenza-like symptoms, fatigue, neutropenia, and thrombocytopenia during treatment. Moreover, the cost of PEG-IFN was higher.
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After PEG-IFN treatment, most patients obtained sustained virological response, HBeAg seroconversion with or without HBsAg clearance.
However, only 29%-32% of HBeAg-positive CHB patients who received PEG-IFN treatment for 1 year would gain HBeAg seroconversion, and only 3%-7% of them could eradicate the virus inside the liver cell. 5, 6 It is indicated that sustained virological response, HBeAg seroconversion, and HBsAg seroclearance were the ideal clinical outcomes of IFN treatment. 1 However, not all CHB patients could obtain satisfactory ending by PEG-IFN treatment. Consequently, identification of molecular biomarkers that can identify CHB patients sensitive to IFN therapy would be useful in the clinic.
Increasing evidences indicate that host genetics act as an import-
ant role in the natural history of HBV-related liver disease and the response of treatment. Single nucleotide polymorphisms (SNPs) were found to be associated with antiviral therapy in CHB patients. Cheng et al 7 found that rs3077 GG and rs9277535 GG were strongly related to a higher response rate to IFN treatment. Zhu et al 8 reported that
HLA-DR and HLA-DQ were also associated with treatment response to IFN therapy in CHB patients.
Most recently, it has been reported that vitamin D (VD) deficiency was associated with the low response rate to IFN plus ribavirin in HCV genotype 1. The theory was to inhibit the effect of VD on the HCV-RNA replication. 9 The relationship between VD and liver disease is The aim of our study was to evaluate a possible association be- 
| MATERIALS AND METHODS

| Subjects
| Definitions of treatment responses
Treatment response was determined after 48 weeks of treatment based on the guideline of prevention and treatment for chronic hepatitis B (2010 version).
14 HBsAg seroclearance was defined as HBsAg 
| SNPs selection
HapMap dataset was used to select the tagger SNPs (TagSNPs). 
| CYP27B1 (rs4646536 and rs10877012) polymorphism genotyping
Genomic DNA was isolated from blood samples using the DNA Extraction Kit (Tiangen Biotech Co, Ltd, Beijing, China). We evaluated the SNPs in patients who have agreed to undergo genetic analyses and for whom blood samples were available. The genotypes of rs4646536 and rs10877012 were analyzed by direct sequencing. These were retrospectively analyzed from serum samples which were obtained at baseline before treatment initiation.
| 1,25(OH
| Laboratory measurements
Serum HBV DNA, HBeAg, and HBsAg were quantified in samples taken at baseline, week 12, and at the end of IFN treatment.
HBsAg and HBeAg were quantified with the Chemiluminescence Microparticle Immuno Assay on Abbott Architect I2000. ALT level was measured by rate assay on Olympus AU2700. Serum levels of HBV DNA were quantified by qPCR (the lower limit of quantification 500 IU/mL) on ABI7500. HBV genotypes were determined by realtime PCR-Fluorescence Probing on ABI7500.
| Statistical analysis
Statistical analysis was performed using IBM SPSS version 18.0 (SPSS Inc, Chicago, IL, USA) and GraphPad Prism software version 5.0 (GraphPad Software, San Diego, CL, USA). Associations between variables were tested using Student's t test and chi square test. The genetic association analysis consisted of an additive model as well as a haplotype block analysis. Binary logistic regression modeling was used to identify independent factors associated with the outcome at the end of treatment. All statistical tests were two-sided and evaluated at the 0.05 level of significance.
| RESULTS
| Patient characteristics
A total of 87 HBeAg-positive CHB patients treated with IFN were collected. The characteristics of the enrolled patients are shown in 
| Prevalence of CYP27B1 Genotypes
There were significant differences among the groups both in allele frequencies and genotype distributions. CYP27B1 genotype frequencies were 20.7%, 42.5%, and 36.8% for TT, TC, and CC at rs4646536, respectively; 58.6%, 4.6%, and 36.8% for GG, GT, and TT at rs10877012, respectively. The allele frequencies were 42% and 58% for T and C at rs4646536, respectively; 49% and 51% for G and T at rs10877012, respectively.
| Relationship between CYP27B1 polymorphisms and treatment response
We found a significant correlation between CYP27B1 polymorphisms and treatment outcome ( Table 2 ). The proportion of individuals with CC genotype at rs4646536 was higher in the NR group than in the CR group (P = .005). Besides, higher frequency of rs4646536 C allele was observed in the NR group (68.97%) than in the CR group (40.62%).
The frequency of allele T at rs10877012 was significantly higher in the NR group (P < .001, OR=0.101). The GG genotype was prevalent in patients with CR (P = .001, OR = 0.087), and patients with TT genotype were more likely to obtain NR of IFN treatment (P = .005, OR = 8.615). .9) 34 (58.6)
The differences in genotype frequencies between any two groups were analyzed using logistic regression models. ORs were calculated as reported within the 95% CI.
CR, compete response; PR, partial response; NR: nonresponse; OR, odds ratio; CI, confidence interval. Data were presented as number (percentage) for every group. *Significant P-value (<.05).
was independently associated with CR, rather than NR after adjustment [P = .006, OR = 0.290, 95%CI (0.117~0.718)]. In addition, haplotype CT appeared to be associated with NR and PR, rather than CR [P < .001, OR = 9.618, 95%CI (0.119-1.084)] (Table 3 ).
| Relationship between 1,25(OH) 2 D 3 and treatment response
Our data showed that baseline concentration of 1,25(OH) 2 > 39.39 pg/ml had higher CR rates at the end of IFN therapy (Table 4) . 
| DISCUSSION
As IFN is generally poorly tolerated and only leads to a successful response in a subgroup of patients, it is essential to select patients who have the high probability to achieve a response before initiating therapy. The response rate to treatment of CHB was strongly influenced by genetic factors such as HLA-DR, HLA-DP, HLA-DQ, IL-28B, and IFNAR. 7, 8, [15] [16] [17] [18] [19] [20] In the CHB treatment, the role of CYP27B1 is still ambiguous. The relationship between VD and liver disease is reciprocal. Liver and kidneys are required to activate VD by 25(OH)D 3 -1α
hydroxylase, respectively. 10 The VD deficiency has been related to hepatic disease progression. 21 However, the role of CYP27B1 and its polymorphisms has not been studied yet in the treatment of HBeAgpositive CHB patients by IFN. In the current study, we have shown for the first time that polymorphisms of the CYP27B1 gene are associated with response to IFN 12 months post-treatment in CHB patients.
In the treatment of CHB, the role of 1,25(OH) 2 D 3 has been demonstrated as an important immune modulator in IFN-signaling pathways, in which the immunomodulatory effect was given the regulatory T cell. 13 The There were some differences between our results and literatures. That may due to the different criteria of grouping, the diverse strategy in IFN treatment, and the different subjects enrolled in the study. Obviously, our study has certain limits that may be, at least partially, responsible for some results discordant to those already published in other studies: First, few cases were included in our study; second, the different basis for grouping, may be due to the different guidance in different countries; third, the patient type was limited. Our cohort only included HBeAg-positive CHB patients with genotype B or C, the HBeAg-negative patients, or patients with genotype A and genotype D which were prevalent in the occident need to be considered in the following studies; furthermore, ethnic variation may be another important reason. However, based on the important predictive value of CYP27B1 gene polymorphisms in IFN therapy, the results of our research will be a reference for the future study.
In conclusion, our study reveals that polymorphisms in the CYP271B1 may associate with the response to IFN therapy. In future research, multicenter studies with more samples needed to carry out and to fully validate the significance of these findings.
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